



Market Announcement

25 March 2024

Clarity Pharmaceuticals Ltd (ASX: CU6) – Trading Halt (2+1)

Description

The securities of Clarity Pharmaceuticals Ltd ('CU6') will be placed in trading halt at the request of CU6, pending it releasing an announcement regarding the outcome of the institutional component of the accelerated entitlement offer. Unless ASX decides otherwise, the securities will remain in trading halt until the commencement of normal trading on Thursday, 28 March 2024.

Issued by

ASX Compliance

Lisa Banh/Inderprit Singh
Compliance Adviser, Listings Compliance (Sydney)
ASX Limited
20 Bridge Street
Sydney NSW 2000

By Email: tradinghaltssydney@asx.com.au

Monday 25 March 2024

Request for Trading Halt

Dear Ms Banh and Mr Singh

Clarity Pharmaceuticals Ltd (ACN 143 005 341) (ASX: CU6) (the **Company** or **Clarity**) requests an immediate halt in trading of Clarity's securities effective prior to the commencement of trading today pursuant to ASX Listing Rule 17.1.

Clarity provides the following information for the purposes of ASX Listing Rule 17.1:

- the trading halt is requested pending the planning and preparation for, and an announcement by the Company in relation to, an equity raising by way of a pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) and institutional placement (**Placement**);
- Clarity requests that the trading halt remain in place until the commencement of trading on Thursday, 28 March 2024; and
- Clarity is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

The Company requests the three day trading halt in response to press speculation regarding the capital raising and the need to finalise the planning, preparation and execution of the same.

Please contact me if there are any queries regarding the request.

Your sincerely,

Robert Vickery
Company Secretary